DARE - Dare Bioscience, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

DARE

DARE BIOSCIENCE, INC.

NASDAQ

$0.73

▼ DOWN 0.50% (-0.00)

KEY STATISTICS

Market Cap$11.01 M

52w High$3.78

52w Low$0.72

Dividend Yield—

Frequency—

P/E-0.77

Volume354.16K

Shares Out.14.98M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Sabrina Martucci Johnson

COMPENSATION 2026

Salary$518,725

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$14,000

Total$801,081

ABOUT

SECTOR

Healthcare

WENT PUBLIC

April 10, 2014

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$12.00

Target Low$12.00

Target Median$12.00

Target Consensus$12.00

UPCOMING EARNINGS

DateNov 12, 2026

DayThursday

Rev. Est.$2.02M

NOV

THU

SPLIT RECORD

DATE	TYPE	RATIO
2024-07-01	Reverse	1:12
2017-07-20	Reverse	1:10

PRICE

$0.73 ▼ DOWN 0.50% (−$0.00)

OVERLAYS

About Dare Bioscience, Inc.

https://darebioscience.com ↗

Daré Bioscience, a clinical-stage biotech, develops women's health products—including contraceptives, fertility, and vaginal health therapies—such as XACIATO, Ovaprene, and Sildenafil Cream, with several in advanced clinical and pre-clinical stages.

INDUSTRY

Biotechnology

A PRODUCT DARE BIOSCIENCE, INC. IS KNOWN FOR

DARE to PLAY

DARE to PLAY is a clinically-backed topical sildenafil cream for women to enhance genital blood flow and sexual response, with commercial launch expected in Q4 2025 through a 503B outsourcing facility.